Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $508-Report Released on 30 January 2024
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reaffirmed a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $456 to $508, as reported on January 30, 2024.
January 31, 2024 | 7:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on Vertex Pharmaceuticals and raises the price target from $456 to $508.
The increase in price target by Truist Securities is a strong positive signal to investors, suggesting a bullish outlook on Vertex Pharmaceuticals. This could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100